Suven Pharmaceuticals Q4 Results Live : profit falls by 56.95% YOY
Suven Pharmaceuticals Q4 Results Live : Revenue decreased by 31.52% YoY & profit decreased by 56.95% YoY
Suven Pharmaceuticals Q4 Results Live : Suven Pharmaceuticals declared their Q4 results on 30 May, 2024. The topline decreased by 31.52% & the profit decreased by 56.95% YoY. Compared to the previous quarter, the revenue grew by 15.06% and the profit increased by 14.16%.
The Selling, general & administrative expenses rose by 19.97% q-o-q & increased by 53.85% Y-o-Y. The operating income was up by 7.07% q-o-q & decreased by 64.3% Y-o-Y.
The EPS is ₹2.1 for Q4 which decreased by 56.84% Y-o-Y. Suven Pharmaceuticals has delivered 0.29% return in the last 1 week, -4.19% return in the last 6 months and -12.56% YTD return.
Currently, Suven Pharmaceuticals has a market cap of ₹16089.78 Cr and 52wk high/low of ₹768 & ₹469.45 respectively. As of 31 May, 2024, out of 1 analysts covering the company, 1 analyst has given a Strong Buy rating.
The consensus recommendation as of 31 May, 2024, was to Strong Buy.
Period | Q4 | Q3 | Q-o-Q Growth | Q4 | Y-o-Y Growth |
---|---|---|---|---|---|
Total Revenue | 252.93 | 219.82 | +15.06% | 369.36 | -31.52% |
Selling/ General/ Admin Expenses Total | 39.39 | 32.83 | +19.97% | 25.6 | +53.85% |
Depreciation/ Amortization | 17.25 | 12.75 | +35.24% | 11.96 | +44.22% |
Total Operating Expense | 196.83 | 167.43 | +17.56% | 212.24 | -7.26% |
Operating Income | 56.1 | 52.39 | +7.07% | 157.12 | -64.3% |
Net Income Before Taxes | 70.85 | 65.47 | +8.22% | 166.21 | -57.37% |
Net Income | 53.37 | 46.75 | +14.16% | 123.97 | -56.95% |
Diluted Normalized EPS | 2.1 | 1.84 | +14.13% | 4.87 | -56.84% |
FAQs
Question : What is the Q4 profit/Loss as per company?
Ans : ₹53.37Cr
Question : What is Q4 revenue?
Ans : ₹252.93Cr
Stay updated on quarterly results with our results calendar
3.6 Crore Indians visited in a single day choosing us as India's undisputed platform for General Election Results. Explore the latest updates here!